Ajo LP reduced its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 92.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,530 shares of the biotechnology company’s stock after selling 133,176 shares during the period. Ajo LP’s holdings in Exelixis were worth $274,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of EXEL. Norges Bank bought a new position in Exelixis in the 4th quarter worth approximately $54,640,000. Wells Fargo & Company MN increased its position in Exelixis by 320.7% in the 1st quarter. Wells Fargo & Company MN now owns 3,204,443 shares of the biotechnology company’s stock worth $76,266,000 after buying an additional 2,442,773 shares during the period. Oregon Public Employees Retirement Fund increased its position in Exelixis by 1,978.9% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 2,319,939 shares of the biotechnology company’s stock worth $118,000 after buying an additional 2,208,347 shares during the period. Frontier Capital Management Co. LLC increased its position in Exelixis by 350.9% in the 1st quarter. Frontier Capital Management Co. LLC now owns 2,822,208 shares of the biotechnology company’s stock worth $67,169,000 after buying an additional 2,196,279 shares during the period. Finally, Fiera Capital Corp bought a new position in Exelixis in the 4th quarter worth approximately $39,370,000. 78.27% of the stock is currently owned by institutional investors.
Shares of NASDAQ:EXEL opened at $20.05 on Thursday. Exelixis, Inc. has a 1-year low of $13.42 and a 1-year high of $25.31. The company has a market cap of $6.00 billion, a PE ratio of 14.02, a PEG ratio of 0.48 and a beta of 1.98. The company has a current ratio of 7.56, a quick ratio of 7.48 and a debt-to-equity ratio of 0.01.
EXEL has been the topic of several recent analyst reports. Zacks Investment Research raised Exelixis from a “strong sell” rating to a “hold” rating in a research report on Monday, March 4th. BMO Capital Markets initiated coverage on Exelixis in a research report on Friday, February 22nd. They issued a “market perform” rating and a $23.00 price target on the stock. Cowen reaffirmed a “buy” rating and issued a $29.00 price target on shares of Exelixis in a research report on Tuesday, February 26th. Morgan Stanley raised Exelixis from an “underweight” rating to an “equal weight” rating and set a $24.80 price target on the stock in a research report on Monday, March 18th. Finally, ValuEngine raised Exelixis from a “sell” rating to a “hold” rating in a research report on Wednesday, March 6th. Six equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Exelixis has an average rating of “Buy” and a consensus price target of $28.88.
In related news, Director George Poste sold 3,860 shares of the business’s stock in a transaction on Friday, March 29th. The stock was sold at an average price of $23.89, for a total value of $92,215.40. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Patrick J. Haley sold 2,700 shares of the business’s stock in a transaction on Tuesday, March 26th. The shares were sold at an average price of $23.47, for a total value of $63,369.00. The disclosure for this sale can be found here. Insiders have sold a total of 555,930 shares of company stock worth $12,363,512 in the last three months. 4.50% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: This story was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://sportsperspectives.com/2019/06/13/exelixis-inc-nasdaqexel-holdings-reduced-by-ajo-lp.html.
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
See Also: What are Institutional Investors?
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.